文献速递消化内镜胰腺与胆道疾病

瑞马唑仑与丙泊酚用于ERCP深度镇静的多中心随机对照试验

Comparative safety and efficacy of remimazolam versus propofol for endoscopic retrograde cholangiopancreatography with the patient under deep sedation: a multicenter randomized controlled trial.
PubMed 文献 · Gastrointest Endosc · 2025-11-11

这项多中心随机对照试验将396例接受ERCP深度镇静的患者随机分为瑞马唑仑组和丙泊酚组,每组198例。两组镇静效果相当,但瑞马唑仑组患者满意度更高,注射痛及中重度心肺不良事件(不包括低氧血症)更少。瑞马唑仑是ERCP深度镇静安全有效的替代选择。

要点

  • 瑞马唑仑与丙泊酚在ERCP深度镇静中效果相当,操作与恢复时间无显著差异
  • 瑞马唑仑患者满意度更高,注射痛及中重度心肺不良事件更少
  • 丙泊酚、低BMI、心血管疾病及饮酒是心肺不良事件的危险因素

核心结论

  • 瑞马唑仑是ERCP深度镇静中安全有效的丙泊酚替代方案,镇静效果相当,患者满意度更高,注射痛及中重度心肺不良事件更少。

研究设计与样本

  • 多中心随机对照试验,共纳入396例接受ERCP深度镇静的患者,随机分为瑞马唑仑组(n=198)和丙泊酚组(n=198)。

主要发现

  • 两组镇静效果相当,操作时间与恢复时间无显著差异。

临床怎么用

  • 瑞马唑仑可作为ERCP深度镇静的替代方案,尤其适用于镇静相关不良事件风险较高的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: ERCP requires the patient remain in deep sedation, which is most commonly achieved with propofol. Despite its efficacy, however, propofol is associated with adverse events such as hypoxemia and hypotension. Remimazolam, a short-acting benzodiazepine, has emerged as a potentially safer alternative. This multicenter randomized controlled trial aimed to compare the safety and efficacy of remimazolam versus propofol for deep sedation during ERCP. METHODS: A total of 396 patients undergoing ERCP were randomized into the remimazolam (n = 198) or propofol (n = 198) group. The primary endpoint was sedation quality assessed by patient and endoscopist satisfaction. Secondary outcomes included procedural efficacy, incidence of adverse events, and safety parameters. RESULTS: Sedation efficacy was comparable between the groups, with no significant differences in procedural or recovery times. However, patient satisfaction was significantly greater with remimazolam (9.00 [7.00-10.00]) than propofol (8.00 [6.00-10.00]; P = .024). Remimazolam significantly reduced both injection-site pain (19.7% vs 31.3%; P = .008) and moderate-to-severe cardiopulmonary events excluding hypoxemia (1.01% vs 4.54%; P = .032). Multivariable analysis identified propofol (risk ratio [RR], 7.47; P = .018), low body mass index (RR, 1.23; P = .028), cardiovascular disease (RR, 6.44; P = .044), and alcohol intake (RR, 7.57; P = .011) as significant risk factors for cardiopulmonary adverse events. CONCLUSIONS: Remimazolam is a safe and effective alternative to propofol for sedation during ERCP, demonstrating comparable sedation efficacy, greater patient satisfaction, reduced injection-site pain, and fewer moderate-to-severe cardiopulmonary adverse events. Remimazolam thus has strong clinical utility, particularly in patients at a greater risk of sedation-related adverse events.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Han SY, Oh D, Choe JW, et al. Comparative safety and efficacy of remimazolam versus propofol for endoscopic retrograde cholangiopancreatography with the patient under deep sedation: a multicenter randomized controlled trial. Gastrointest Endosc. 2025. PMID: 41232615. doi:10.1016/j.gie.2025.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。